GreenLight Biosciences EBIT

GreenLight Biosciences (GRNA) currently reports a EBIT of $-160M as of March 2023. That compares with $-29M in the prior-year period — down 438.2% year over year. That is below the sector sector average of $-6.4M. Use the charts on this page to explore GreenLight Biosciences's EBIT history and peer comparisons.

GreenLight Biosciences's EBIT decreased from $-29M to $-160M — a 438.2% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

GreenLight Biosciences's EBIT of $-160M is lower than the its sector sector average of $-6.4M. That is roughly 2327.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

GreenLight Biosciences reported $-160M in EBIT as of March 2023. That compares with $-29M in the prior-year period — down 438.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-160M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-6.4M. From there, open related valuation or income-statement pages for GreenLight Biosciences, and consider following GRNA for alerts when major investors trade the stock.